{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-22-000102","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.902999+00:00","generated_at":"2026-06-21T08:58:36.922466+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gossamer Bio's Phase 2 TORREY study meets primary endpoint; seralutinib reduces PVR in PAH","bullets":["Phase 2 TORREY met primary endpoint: placebo-corrected PVR reduction of 96.1 dynes (14.3%, p=0.031).","Secondary endpoint 6MWD numerically favored seralutinib by 6.5 meters (not statistically significant).","In FC III patients: 21% PVR reduction (p=0.043) and 37m 6MWD improvement (p=0.048) vs placebo.","NT-proBNP reduced by 408.3 ng/L at Week 24 (p=0.0012); right heart structure/function improved.","Seralutinib well tolerated; cough most common TEAE (43% vs 38% placebo), no subdural hematomas."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-22-000102","json":"https://secwatch.observer/filing/0001728117-22-000102.json","markdown":"https://secwatch.observer/filing/0001728117-22-000102.md","text":"https://secwatch.observer/filing/0001728117-22-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000102/0001728117-22-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000102/goss-20221206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:58:36.922466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}